SCHEMBL20715708

SCHEMBL20715708

CCCCCCC(CC)CCCNC(N)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GNAI3 P08754 1/20 0.46
▸ GNAO1 P09471 1/20 0.46
▸ GNAI1 P63096 1/20 0.46
▸ EPHX1 P07099 8/20 0.46
▸ RRM1 P23921 1/20 0.45
▸ DPP7 Q9UHL4 2/20 0.45
▸ CA2 P00918 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ SIRT6 Q8N6T7 1/20 0.42
▸ SIRT1 Q96EB6 1/20 0.42
▸ CASP2 P42575 1/20 0.42
▸ MMP9 P14780 1/20 0.41
▸ MMP8 P22894 1/20 0.41
▸ MMP14 P50281 1/20 0.41
▸ PRSS1 P07477 1/20 0.40
▸ PRSS2 P07478 1/20 0.40
▸ PRSS3 P35030 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20715727 0.93 GNAI3 (0.49) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL24722185 0.93 GNAI3 (0.49) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL27111043 0.91 DPP7 (0.50) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL13073784 0.87 MMP9 (0.40) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL6015326 0.84 FFAR4 (0.53) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL11794051 0.82 EPHX2 (0.50) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL24443524 0.81 GRIK1 (0.54) GNAI3GNAO1GNAI1EPHX1RRM1
SCHEMBL81152 0.81 EPHX1 (0.67) EPHX1RRM1DPP7CASP2
SCHEMBL1820932 0.81 EPHX1 (0.67) EPHX1RRM1DPP7CASP2
SCHEMBL947042 0.81 EPHX1 (0.67) EPHX1RRM1DPP7CASP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 — — US disclosed
US-20200276275-A1 Therapies for Obesity, Diabetes and Related Indications PALATIN TECHNOLOGIES INC (US) 2020-09-03 — — US disclosed
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2019-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200276275-A1 Therapies for Obesity, Diabetes and Related Indications MC4R, GLP1R, MC3R GNAI3 433/4885GNAO1 410/4885GNAI1 477/4885
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 GNAI3 852/4885GNAO1 500/4885GNAI1 687/4885
US-20190040102-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 GNAI3 852/4885GNAO1 500/4885GNAI1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback